Blog
Notes from the Peply team
Compound deep-dives, regulatory updates, guides, and announcements.
Announcement
Introducing Peply — A Neutral Peptide Reference Tool
Peply is a vendor-independent reconstitution calculator and reference layer for peptide and injectable medication data. 24 compounds, 5 stacks, regulatory tracking, zero vendor affiliations.
4 min read
#launch#peptides#calculator#reference
Compound Update
Retatrutide in 2026: The Triple Agonist Explained
Retatrutide is Eli Lilly's Phase 3 investigational triple agonist targeting GIP, GLP-1, and glucagon receptors. Here's what the TRIUMPH data shows, how it compares to semaglutide and tirzepatide, and what regulatory status actually means in 2026.
7 min read
#retatrutide#GLP-1#weight-loss#Eli Lilly